Hyderabad’s AIIMS Bibinagar has emerged as a crucial site for India’s first indigenous dengue vaccine, currently in phase III clinical trials. Led by ICMR and developed in partnership with Panacea Biotec, the single-shot tetravalent vaccine is in its final phase of enrollment.
The study suggests that the prevalence of Covid-19 in the US during spring and summer of 2020 far exceeded the known number of cases and that infection affected the country unevenly.